| Literature DB >> 19135497 |
W Ray Waters1, Mitchell V Palmer, Brian J Nonnecke, Tyler C Thacker, Charles F Capinos Scherer, D Mark Estes, R Glyn Hewinson, H Martin Vordermeier, S Whitney Barnes, Glenn C Federe, John R Walker, Richard J Glynne, Tsungda Hsu, Brian Weinrick, Karolin Biermann, Michelle H Larsen, William R Jacobs.
Abstract
An attenuated Mycobacterium bovisRD1 deletion (DeltaRD1) mutant of the Ravenel strain was constructed, characterized, and sequenced. This M. bovis DeltaRD1 vaccine strain administered to calves at 2 weeks of age provided similar efficacy as M. bovis bacillus Calmette Guerin (BCG) against low dose, aerosol challenge with virulent M. bovis at 3.5 months of age. Approximately 4.5 months after challenge, both DeltaRD1- and BCG-vaccinates had reduced tuberculosis (TB)-associated pathology in lungs and lung-associated lymph nodes and M. bovis colonization of tracheobronchial lymph nodes as compared to non-vaccinates. Mean central memory responses elicited by either DeltaRD1 or BCG prior to challenge correlated with reduced pathology and bacterial colonization. Neither DeltaRD1 or BCG elicited IFN-gamma responses to rESAT-6:CFP-10 prior to challenge, an emerging tool for modern TB surveillance programs. The DeltaRD1 strain may prove useful for bovine TB vaccine programs, particularly if additional mutations are included to improve safety and immunogenicity.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19135497 PMCID： PMC2750035 DOI： 10.1016/j.vaccine.2008.12.018
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641